Evidence map›Paper›PMID 39811383›Full record

ArticlePrzeglad menopauzalny = Menopause review2024

The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high-grade ovarian cancer.

Edyta Leśniak, Emilia Stec-Martyna, Daria Domańska-Senderowska, Hanna Romanowicz, Tomasz Krawczyk, Jan Bieńkiewicz, Andrzej Malinowski, Miłosz Wilczyński

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Przeglad menopauzalny = Menopause review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edyta LeśniakDepartment of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Emilia Stec-MartynaCentral Scientific Laboratory CoreLab, Medical University of Lodz, Lodz, Poland.
Daria Domańska-SenderowskaDepartment of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland.
Hanna RomanowiczDepartment of Pathology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Tomasz KrawczykDepartment of Pathology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Jan BieńkiewiczDepartment of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Andrzej MalinowskiDepartment of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Miłosz WilczyńskiDepartment of Surgical and Endoscopic Gynecology, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ovarian cancer is a significant cause of death among females. MiRNAs, particularly the miR-196 family, can influence tumor progression by targeting specific pathways. Detecting ovarian cancer early is challenging, highlighting the need for additional biomarkers such as miRNAs to improve diagnosis and treatment strategies. Material and methods: Healthy controls and patients with high-grade serous carcinoma ( Results: The study found that miRNA 196a expression was significantly elevated in ovarian cancer patients compared to the control group ( Conclusions: This study supports the critical role of microRNA-196a in the progression of ovarian cancer.

Indexed as

biomarkersmiRNAoncogenesisovarian cancerpolymorphisms

Identifiers

PMID39811383
PMCPMC11726191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.